Optimization of Tubulysin Antibody–Drug Conjugates: A Case Study in Addressing ADC Metabolism-Reference-Cited by-同舟云学术

Optimization of Tubulysin Antibody–Drug Conjugates: A Case Study in Addressing ADC Metabolism

Published:2016-08-02 Issue:11 Volume:7 Page:977-982
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Tumey L. Nathan¹,Leverett Carolyn A.¹,Vetelino Beth¹,Li Fengping¹,Rago Brian¹,Han Xiaogang¹,Loganzo Frank¹,Musto Sylvia¹,Bai Guoyun¹,Sukuru Sai Chetan K.¹,Graziani Edmund I.¹,Puthenveetil Sujiet¹,Casavant Jeffrey¹,Ratnayake Anokha¹,Marquette Kimberly¹,Hudson Sarah¹,Doppalapudi Venkata Ramana¹,Stock Joseph¹,Tchistiakova Lioudmila¹,Bessire Andrew J.¹,Clark Tracey¹,Lucas Judy¹,Hosselet Christine¹,O’Donnell Christopher J.¹,Subramanyam Chakrapani¹

Affiliation:

1. Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

http://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.6b00195

Reference25 articles.

1. Antibody–drug conjugates for cancer therapy

2. Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?

3. Construction of homogeneous antibody–drug conjugates using site-selective protein chemistry